Study measures
| Domain | Construct | Measure | Items | Years | Data source |
| Social position (predictor) | Race | Self-reported racial identification67 | 1 | * | MWCCS core |
| Ethnicity | Self-reported ethnicity identification67 | 1 | 0 | MWCCS core | |
| Income | Self-reported annual gross income67 | 1 | 0–4 | MWCCS core | |
| HIV status | ELISA/Western blot67 | – | 0–4 | MWCSS core | |
| Sexual identity | Self-reported sexual identity66 67 | 1 | 0–4 | MWCCS core | |
| Sexual behaviour | Self-reported: gender of sexual partners since last visit54 | 1–3 | 0–4 | MWCCS core | |
| Intersectional stigma (mediator 1) | |||||
| Intercategorical stigma | InDI-A, InDI-D, InDI-M51 | 31 | 1–4 | Substudy survey | |
| Intracategorical stigma | Intersectional stigma in healthcare settings scale55 | 41 | 1–4 | Substudy survey | |
| Psychosocial syndemic (mediator 2) | |||||
| Current stress | PSS-456 | 7 | 1–4 | MWCCS core | |
| Chronic stress | TICS-E-9 Chronic Stress Screening Scale57 | 9 | 1–4 | Substudy survey | |
| Depression | CES-D-1059 60 | 10 | 1–4 | MWCCS core | |
| Intimate partner violence | RADAR IPV measures58 | 1–5 | 1–4 | Substudy survey | |
| Anxiety | GAD-261 | 2 | 1–4 | Substudy survey | |
| Polydrug use | Past-year use of 2 or more illicit substances at least monthly54 | 0–16 | 1–4 | MWCCS core | |
| Sympathetic adrenal medullary (SAM) system stress response | Heart rate variability76 | – | 2/3 | Local site collection/EPICARE | |
| Hypothalamic-pituitary-adrenal (HPA) axis stress response | Hair cortisol concentration47 | – | 2/3 | Local site collection/Technische Universitat Dresden | |
| Resiliencies (moderators) | |||||
| Social support | Medical Outcomes Study Social Support Survey-4 items (MOS-SS-4)62 | 4 | 1/2 | MWCCS core/substudy survey | |
| Resilience | Brief Resilient Coping Scale63 | 4 | 1 | Substudy survey | |
| Patient–provider relationship strength | Healthcare Relationship Trust Scale64 | 15 | 1–4 | Substudy survey | |
| Mindfulness | Mindful Attention Awareness Scale65 | 5 | 1 | Substudy survey | |
| HIV and NCD syndemic continua of care (outcomes) | |||||
| Healthcare avoidance | Global Healthcare Avoidance Brief Measure73 | 1–2 | 1–4 | Substudy survey | |
| Retention in care for NCDs | Past-year healthcare utilisation specific to diabetes, hypertension and/or dyslipidaemia | 3 | 1–4 | Substudy survey | |
| Treatment for NCDs | Past-year prescriptions specific to diabetes, hypertension and/or dyslipidaemia | 0–3 | 1–4 | Substudy survey | |
| NCD treatment adherence | Past-year adherence to medications for diabetes, hypertension and/or dyslipidaemia | 0–3 | 1–4 | Substudy survey | |
| Retention in care for HIV | Past-year healthcare utilisation specific to HIV care67 | 0–1 | 1–4 | MWCCS core | |
| Treatment for HIV | Past-year prescriptions specific to HIV67 | 0–5 | 1–4 | MWCCS core | |
| HIV treatment adherence | Past-year adherence to medications for HIV67 72 | 0–5 | 1–4 | MWCCS core | |
*Year 0 refers to data collected from the most recent MWCCS core visit completed prior to enrolment in this study.
GAD-2, Generalised Anxiety Disorder 2-item; InDI, Intersectional Discrimination Index; IPV, intimate partner violence; MWCCS, MACS/WIHS Combined Cohort Study; NCD, non-communicable disease; PSS-4, Perceived Stress Scale; TICS-E-9, Trier Inventory for Chronic Stress.